All News

ABS0450 ⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients ➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97) ➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi #ACR23 @RheumNow https://t.co/yydS20hNzM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
No more underpowered long-term safety studies We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA Minus that, I plan to go 100% TOFA when it becomes generic in 2026 @RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO
Mike Putman EBRheum ( View Tweet)
AS pts on UPA for 52 wks who were active or healthy weight/underweight at BL generally experienced greater decreases from BL in ASDAS-CRP and BASDAI vs pts who were inactive or overweight/obese. #ACR23 Abs #0540 https://t.co/OfgbmYUoAu @rheumno https://t.co/liptgbK2hJ
Dr. Rachel Tate  ( View Tweet)
#ACR23 #SGLT2 inhibitors assoc with ⬇️ urate ⬇️ flares if #gout ⬇️mortality impact on #metabolicSyndrome ✅ https://t.co/ZIqDqirqar

Dr Gurdeep S Dulay  ( View Tweet)

#ACR23 Scleroderma renal Crisis (SRC) May precede skin involvement also. RISK FACTORS • Early diffuse skin disease - 2-3 years from SSc onset, median 8 months • Anti-RNA polymerase III (60%) • Use of corticosteroids - >15 mg/d or low doses for longer time https://t.co/RSIxEXLdX7
Aditya Burje AdityaBurje ( View Tweet)
#ACR23 Abstr#0785 So many debates re: HCQ dose 5mg/kg/d vs 6.5mg/kg/d - could blood monitoring help? A cohort study showed HCQ levels 750-1100 ng/mL was associated with reduced risk of #lupus activity by 76-90%. Need validation & assoc with retinal toxicity risk @RheumNowNews https://t.co/oRCHUG2dVA
Md Yuzaiful Md Yusof  ( View Tweet)
#ACR23 Abstr#0548 Is there a risk prediction tool to help exclude non-immune pathology for Rheumatologists with newly referred ANA+? 3-yr data showed 3 BL markers: IFN score B, criteria No & FH of RMD had 98% specificity. Cd help inform early Tx trials in High Risk @RheumNowNews https://t.co/DCAg4EwM9d
Md Yuzaiful Md Yusof  ( View Tweet)
TNF AND IL17 was equally effective in Axial SpA! #ACR23 #Reviewcourse https://t.co/oofQkvsJ3f
Nouf Al hemmadi  ( View Tweet)
Need to improve our conversations with young adults on methotrexate about alcohol and sexual activity. They are often uncomfortable and/or dishonest about telling. Great work from @McMasterU by undergrad Matthew Sholdice #transition @drgrainnemurray #ACR23 https://t.co/wwyZLQVA51
Catherine Hill CatherineL_Hill ( View Tweet)
Extrahepatic manifestations of #hepatitisC #ACR23 https://t.co/sb0AQofkvt

Links:

dr hanady manasfi hanadymanasfi ( View Tweet)
I would like to participate in a prospective trial for prevention on RA by pizza consumption. #ACR23 https://t.co/Y96xFolUgM

Adela Castro AdelaCastro222 ( View Tweet)

#ACR23 #ReviewCourse - By Dr. Francesco Boin. Systemic Sclerosis Screening for Organ Involvement. This slide is a true "take home slide" @ACRheum #ACRambassador https://t.co/4FVYWJjHyV
Anne Troldborg  ( View Tweet)
Or to quote the great Murray Urowitz @UHN "a #lupus pregnancy has four trimesters"! #ACR23 https://t.co/Iw2S81tiTH

Ian N Bruce  ( View Tweet)

✅ Question to YOU attending #ACR23 ➡️ We're almost at the end of 2023 ⌛and many great #lupus data are being presented at @ACRheum Convergence 2023 in San Diego 👍 What would YOU update/change 🔄 regarding the management of #lupus in 2024 compared to 2023? 🧭 https://t.co/xpSXjuDjyr
Laurent ARNAUD  ( View Tweet)
Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopic #polyangiitis (Abstract 0725 https://t.co/7x34Hr0OMP) @TerrierBen #ACR23 #ACRambassador https://t.co/D8UfZvXQCl
Alessia Alunno  ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on SpA Update: Radiographic and Non-Radiographic AS - Dr. Alexis Ogdie 1. Workup of inflammatory back pain: History, exam, CRP, HLA-B27, SI joint films, MRI pelvis (STIR images, no need for contrast). Response to NSAIDs not actually… https://t.co/M0W6UNsPxF https://t.co/7k3xl1RXZz
Paul Sufka, MD psufka ( View Tweet)
ABS0524: ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA ➡️active dz, HLAB27+, 2 or more AAU flares ⭐️CZP reduced AAU flare rate by 87% #ACR23 @RheumNow #ACRBest https://t.co/rW0N18agMO
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on Update on Relapsing Polychondritis - Dr. Marcela Ferrada 1. Be aware of common/uncommon manifestations (see slide). Affects more than just the ear!!! 2. Collagen II antibodies: not really sensitive or specific for diagnosis. Biopsy… https://t.co/f5xGtcMzk3 https://t.co/xVigSabXDb
Paul Sufka, MD psufka ( View Tweet)
Are we tapering steroids too rapidly? Real world experience: steroid tapering in severe #AAV based on #PEXIVAS protocol noted higher rates of dz progression, relapse, ESRD, death. Risk greatest when creatinine > 300umol/L and w/RTX induction #Plenary1 #ACR23 Abst#0725 #ACrBest https://t.co/Rtv7vkzUUD
TheDaoIndex KDAO2011 ( View Tweet)
ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno
Adela Castro AdelaCastro222 ( View Tweet)
×